{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:55Z","timestamp":1792601455265,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Bumetanide, a loop diuretic, was identified as a candidate drug for repurposing for Alzheimer's disease (AD) based on its effects on transcriptomic apolipoprotein E signatures. Cross\u2010sectional analyses of electronic health records suggest that bumetanide is associated with decreased prevalence of AD; however, temporality between bumetanide exposure and AD development has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We evaluated Medicare claims data using Cox proportional hazards regression to evaluate the association between time\u2010dependent use of bumetanide and time to first AD diagnosis while controlling for patient characteristics. Multiple sensitivity analyses were conducted to test the robustness of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>We sampled 833,561 Medicare beneficiaries, 60.8% female, with mean (standard deviation) age of 70.4 (12). Bumetanide use was not significantly associated with AD risk (hazard ratio 1.05; 95% confidence interval, 0.99\u20131.10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Using a nationwide dataset and a retrospective cohort study design, we were not able to identify a time\u2010dependent effect of bumetanide lowering AD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Bumetanide was identified as a candidate for repurposing for Alzheimer's disease (AD).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We evaluated the association between bumetanide use and risk of AD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We used Medicare data and accounted for duration of bumetanide use.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Bumetanide use was not significantly associated with risk of AD.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.13872","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T21:29:05Z","timestamp":1719005345000},"page":"5236-5246","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease"],"prefix":"10.1002","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8721-6049","authenticated-orcid":false,"given":"Jasmine","family":"Morales","sequence":"first","affiliation":[{"name":"Herbert Wertheim School of Public Health &amp; Human Longevity Science University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loki","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health &amp; Human Longevity Science University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Z.","family":"LaCroix","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health &amp; Human Longevity Science University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladdin H.","family":"Shadyab","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health &amp; Human Longevity Science University of California, San Diego  La Jolla California USA"},{"name":"Division of Geriatrics, Gerontology, and Palliative Care Department of Medicine University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Xu","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health &amp; Human Longevity Science University of California, San Diego  La Jolla California USA"},{"name":"Department of Mathematics University of California, San Diego  La Jolla California USA"},{"name":"Halicioglu Data Science Institute University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Silverman","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study University of California San Diego, School of Medicine  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study University of California San Diego, School of Medicine  La Jolla California USA"},{"name":"Department of Neurosciences University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences University of California, San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Powder for Pennies Collaboration","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1323868"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32399-1"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_9_7_1","unstructured":"US Food and Drug Administration Press Release.FDA Converts Novel Alzheimer's disease Treatment to Traditional Approval.2023. Accessed: October 01 2023.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010converts\u2010novel\u2010alzheimers\u2010disease\u2010treatment\u2010traditional\u2010approval"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.1749"},{"key":"e_1_2_9_9_1","unstructured":"US Food and Drug Administration.Full Prescribing Information.2023. Accessed November 20 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269s000lbl.pdf"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0397-4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2023_692"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00122-7"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2023.1211571"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1190402"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.49370"},{"key":"e_1_2_9_16_1","unstructured":"Services CfMM.Centers for Medicare and Medicaid Services. Chronic Condition Data Warehouse. Chronic Conditions. 2013\u20102023. Accessed May 12 2024.https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories-chronic"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00452-3"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/02699052.2016.1199898"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/02699052.2020.1849801"},{"key":"e_1_2_9_20_1","unstructured":"Services CfMM.Billing and Coding: Cataract Surgery in Adults.2024. Accessed February 2024.https:\/\/www.cms.gov\/medicare\u2010coverage\u2010database\/view\/article.aspx?articleid=57195#:~:text=For%20Complex%20Cataract%20Surgery%20(CPT perception%20of%20the%20surgical%20difficulty)"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp352"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.631"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2572"},{"issue":"18","key":"e_1_2_9_24_1","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","journal-title":"Circulation"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.07.012"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022206"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-017-0724-3"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0213"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-023-00588-3"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.015150"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.13872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:18:45Z","timestamp":1759943925000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.13872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/alz.13872"],"URL":"https:\/\/doi.org\/10.1002\/alz.13872","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"2023-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}